Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Background: Receptor-interacting protein kinase 1 (RIPK1), a serine/threonine protein kinase, is mainly activated by pro-inflammatory cytokines and pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its activation could result in apoptosis, necroptosis, or inflamm...

Full description

Saved in:
Bibliographic Details
Main Authors: Norberto Chavez-Tapia, Muneeba Ahsan Sayeed, Shobha Luxmi, Douglas J. Kasper, Fenchao Xue, Yang Shen, Weiliang Fan, Wei Yuan, Bin Du
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Journal of Intensive Medicine
Subjects:
COVID-19
Phase 1b trial
Receptor-interacting protein 1
RIPK1
RIPK1 inhibitor
SIR1-365
Online Access:http://www.sciencedirect.com/science/article/pii/S2667100X24000938
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items